The clinical foundation of the analysis is formidable. ENZAMET, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group and the NHMRC Clinical Trials Centre at the University of Sydney, randomized 1125 men across 83 sites in six countries between March 2014 and March 2017. Half received testosterone suppression plus enzalutamide, a potent androgen receptor pathway inhibitor; the other half received testosterone suppression plus an older non-steroidal antiandrogen such as bicalutamide. Earlier results showed enzalutamide cut the risk of death by roughly 30 percent and the risk of progression by more than half, with benefits maintained out to five years. The new study asked a harder question: what do those gains actually cost?

Unlike most economic evaluations, which lean on mathematical models projecting decades into the future, this analysis used prospectively collected, patient-level data from the trial itself. The researchers tracked hospitalizations, including intensive care and general ward days and emergency department visits, through electronic case report forms. They also linked Medicare and Pharmaceutical Benefits Scheme claims for roughly 45 percent of participants, capturing primary care visits, diagnostic tests, and prescription medicines outside the trial. Quality of life was measured with the EuroQol EQ-5D-5L questionnaire at baseline and then every twelve weeks, generating more than 15,000 individual assessments from 98 percent of participants. The result is an unusually grounded portrait of what treatment actually costs a health system.

The health gains were substantial. Over the first sixty months, men on enzalutamide accrued a mean of 4.25 life-years compared with 3.98 for those on older antiandrogens, and 3.78 progression-free life-years versus 2.66. Adjusted for quality of life, the enzalutamide group gained 0.15 additional quality-adjusted life years, or QALYs, after discounting. Interestingly, while on treatment, the enzalutamide group reported slightly lower utility scores, 0.783 versus 0.810, a difference the authors note did not exceed the minimally important clinical difference of 0.03 for Australian cancer patients, meaning patients on the newer drug did not feel meaningfully worse day to day.

The costs, however, were dominated by the drug itself. At the Australian PBS-listed price of AUD$33 per tablet, taken four tablets daily, enzalutamide accumulated roughly AUD$84.3 million in drug costs across the trial, against under AUD$1 million for the comparator. Per patient, the enzalutamide strategy added AUD$127,262 in discounted costs over five years. Dividing that by the 0.15 QALY gain yields an incremental cost-effectiveness ratio of AUD$835,580 per QALY gained, and AUD$543,880 per life-year saved. Australia’s implicit willingness-to-pay threshold sits near AUD$50,000 per QALY. The drug therefore exceeded the threshold by more than sixteen-fold, a figure consistent with earlier modelled estimates from the United States and China, which reported ratios between roughly US$225,000 and US$509,000 per QALY.

The analysis also uncovered a striking offset that models often miss: once the drug price is excluded, enzalutamide actually saved money. Men on the newer drug spent longer in hospital while on treatment, partly reflecting higher rates of falls and fractures, but they spent far less time in the expensive, progressive, late phase of disease. Total non-drug healthcare costs over five years came to about AUD$60,000 per enzalutamide patient versus AUD$81,300 per comparator patient, a saving of AUD$21,300. In other words, keeping men progression-free longer genuinely reduces downstream spending; the economics fail almost entirely because of the price of the tablets.

Sensitivity analyses made the pricing story vivid. If the per-tablet cost fell to AUD$3, the price of generic versions available in developing countries, enzalutamide became the dominant strategy, costing less and delivering more. At AUD$6.72 per tablet, about 20 percent of the current PBS price, it would meet the AUD$50,000 per QALY threshold. At Denmark’s price of AUD$67 per tablet, the ratio ballooned to nearly AUD$1.85 million per QALY. Probabilistic simulation across 100,000 Monte Carlo replications gave enzalutamide only a 6 percent probability of being cost-effective at the Australian threshold, rising to 16 percent at AUD$100,000. The authors calculate that the price would need to fall by roughly 80 percent for the drug to represent good value at current thresholds.

A further finding deserves attention from clinicians and patients alike. Enzalutamide was associated with higher rates of musculoskeletal complications: falls occurred at 4.1 versus 1.8 per 100 patient-years, and fractures at 2.0 versus 1.1, compared with older antiandrogens. Prescription claims for musculoskeletal and nervous system medications were correspondingly higher in the enzalutamide group. A recent systematic review of eleven randomized trials confirms this signal across the class of potent androgen receptor inhibitors. The authors emphasize that these events are at least partially preventable, and that bone-protective strategies, if properly evaluated and implemented, could improve both the clinical and the economic case for the drug.

The study has limitations the authors acknowledge candidly. Detailed primary care cost data were available only for consenting Australian participants, and trial participants tend to be healthier than the broader population of men with metastatic prostate cancer. The analysis covered only the first five years, during which about 60 percent of enzalutamide patients remained on treatment, and reasons for healthcare use were not captured, making it hard to attribute costs precisely to toxicity. Still, the implications are hard to escape. The clinical benefit of enzalutamide in metastatic hormone-sensitive prostate cancer is real and durable, but at current prices it is priced out of reach of standard cost-effectiveness criteria in Australia and elsewhere. Only five of 23 European health technology assessment agencies offer unrestricted reimbursement in this setting. As patents expire and generics emerge, the arithmetic will change dramatically; until then, the value of this life-extending drug depends less on its biology than on its price.

Subject of Research: Cost-effectiveness of enzalutamide versus standard non-steroidal antiandrogens as first-line therapy for metastatic hormone-sensitive prostate cancer

Article Title: Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)

Article References: Law, C. K., Stockler, M. R., Martin, A. J., Davis, I. D., Sweeney, C. J., & Morton, R. L. (2026). Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304). eClinicalMedicine, 100, Article 104207. https://doi.org/10.1016/j.eclinm.2026.104207

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104207

Keywords: enzalutamide, prostate cancer, cost-effectiveness, ENZAMET trial, QALY, androgen receptor inhibitor, metastatic hormone-sensitive prostate cancer, health economics, drug pricing, bone fractures, randomized controlled trial, Pharmaceutical Benefits Scheme

A new study published in BMC Health Services Research offers one of the first answers to that question for Taiwan. A team of researchers from the National Defense Medical University and Tri-Service General Hospital, led by corresponding author Ping-Hsuan Hsieh, constructed a formal economic evaluation comparing atogepant with placebo for the preventive treatment of episodic migraine in adults, viewed entirely through the lens of Taiwan’s National Health Insurance system. The work matters because cost-effectiveness is intensely local. A drug that looks like a bargain in one country can look extravagant in another, depending on drug prices, health care utilization patterns, and, crucially, how much a society is willing to pay for an additional year of good health.

The methodological backbone of the study is a Markov model, a standard but powerful tool in health economics. Markov models divide a population into discrete health states and then simulate how individuals move between those states over time, with each transition governed by a probability drawn from clinical trial data. In this case, the researchers defined health states by monthly migraine days, the metric that both clinicians and regulators use to judge whether a preventive therapy is working. Patients cycled through the model in twelve-week intervals over a one-year horizon, a design that mirrors the typical duration of the pivotal trials and keeps the extrapolation burden modest. Treatment discontinuation was built into the model, acknowledging that real-world patients stop preventive drugs far more often than trial participants do.

The clinical engine of the model came from the Phase III ADVANCE trial, the landmark randomized study that established atogepant’s efficacy for episodic migraine. In that trial, patients receiving atogepant experienced meaningful reductions in monthly migraine days compared with placebo, and the transition probabilities derived from those results allowed the Taiwanese team to project how a treated population would distribute across health states over the simulated year. On the cost side, the researchers turned to a source that gives the analysis its local credibility: Taiwan’s National Health Insurance claims data. Rather than importing cost estimates from foreign settings, they extracted real reimbursement figures for outpatient visits, emergency department use, and hospitalization, capturing the actual resource consumption of migraine patients within the system that would ultimately pay for the drug.

The benefits side of the ledger was measured in quality-adjusted life-years, or QALYs, the workhorse metric of cost-utility analysis. A QALY combines survival with health-related quality of life, weighting each year of life by the quality of that year on a scale where one represents perfect health and zero represents death. Migraine rarely kills, which makes the quality-of-life component dominant in this disease area. Patients in the model accrued utility according to their migraine frequency state, with fewer monthly migraine days translating into higher quality of life. Here, however, the researchers confronted a familiar problem in health technology assessment: Taiwan lacks its own utility values for migraine frequency states, so the model had to rely on non-local utility inputs, a limitation that would prove central to interpreting the results.

The base-case findings placed atogepant in an interesting middle zone. Compared with placebo, atogepant generated an incremental cost of 1,766 US dollars and a gain of 0.032 QALYs over the one-year horizon, yielding an incremental cost-effectiveness ratio, or ICER, of 55,749 US dollars per QALY gained. To make sense of that number, health economists conventionally benchmark ICERs against a country’s gross domestic product per capita, a practice popularized by the World Health Organization’s historical guidelines. Taiwan’s GDP per capita stands at roughly 34,040 US dollars, so the atogepant ICER fell between one and two times GDP per capita. Under that framework, the drug is not automatically considered cost-effective at the strictest threshold of one times GDP, but it sits comfortably within the range that many health systems treat as potentially acceptable, particularly for therapies addressing conditions with substantial unmet need.

Because every economic model rests on assumptions that may not hold, the researchers subjected their results to a battery of sensitivity analyses. Deterministic one-way analysis, which varies each parameter individually while holding the rest constant, revealed that the single most influential driver of cost-effectiveness was the utility value assigned to the healthiest state in the model, the state of having zero to three monthly migraine days. This finding is intuitive once unpacked: if avoiding migraines produces only a small quality-of-life improvement, then the QALY gain from an effective preventive drug shrinks, and the cost per QALY balloons. If it produces a large improvement, the opposite occurs. Since that utility value was imported rather than measured locally, the entire cost-effectiveness conclusion hinges on a number that may or may not reflect how Taiwanese patients actually experience migraine freedom.

The probabilistic sensitivity analysis added a second layer of nuance by running the model thousands of times while simultaneously sampling every parameter from its uncertainty distribution. The result was a cost-effectiveness acceptability curve showing how the probability that atogepant is cost-effective changes as society’s willingness to pay rises. At a threshold of one times Taiwan’s GDP per capita, atogepant had only a 2.9 percent chance of being cost-effective. At two times GDP per capita, that probability climbed to 74.4 percent, and at three times GDP per capita it reached 96.0 percent. The tipping point, where the probability crossed fifty percent, came at a willingness to pay of approximately 56,300 US dollars per QALY. In plain terms, whether atogepant is a good buy depends almost entirely on how much value Taiwan’s health system assigns to relieving the burden of episodic migraine, and the drug becomes the more likely-than-not choice just above the two-times-GDP threshold.

The authors are appropriately candid about the limits of their work, describing the study as a baseline, proof-of-concept assessment rather than a definitive verdict. Beyond the reliance on non-local utility values, the comparison against placebo, while methodologically clean, sidesteps the question that payers ultimately care about most: how atogepant performs against the preventive therapies already in use, from older oral agents to the injectable CGRP monoclonal antibodies. The one-year horizon, chosen to align with trial evidence, also cannot capture longer-term effects, and the model did not incorporate indirect costs such as lost workplace productivity, which for migraine are often larger than direct medical costs. The researchers call for future evaluations to integrate Taiwan-specific quality-of-life data and to employ network meta-analyses positioning atogepant against active comparators.

Even with those caveats, the study marks a meaningful step for evidence-based drug policy in Asia. Taiwan’s National Health Insurance is renowned for delivering universal coverage at remarkably low administrative cost, but that efficiency depends on disciplined decisions about which new technologies to adopt. By grounding an atogepant evaluation in local claims data and transparent GDP-based thresholds, the research team has created a template that other middle- and high-income health systems can adapt, while simultaneously flagging exactly where local data collection, particularly patient-reported quality of life across migraine frequency states, would deliver the greatest payoff. For the millions of people whose migraines could be prevented by CGRP-targeted therapy, the message is one of cautious optimism: the science works, the economics are within reach, and the remaining uncertainty is now precisely mapped for the next generation of studies to resolve.

Subject of Research: Cost-effectiveness evaluation of atogepant versus placebo for preventive treatment of episodic migraine in Taiwan

Article Title: Economic evaluation of atogepant compared to placebo for the preventive treatment of episodic migraine in Taiwan

Article References: Fang, C.-Y., Lin, T.-K., Yang, F.-C., Liu, Y., Ruan, Y.-Z., & Hsieh, P.-H. (2026). Economic evaluation of atogepant compared to placebo for the preventive treatment of episodic migraine in Taiwan. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15776-5

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15776-5

Keywords: atogepant, CGRP antagonist, episodic migraine, cost-effectiveness, health economics, QALY, ICER, Markov model, Taiwan National Health Insurance, migraine prevention, pharmacoeconomics, health technology assessment

The study, conducted by researchers at Pfizer Japan, IQVIA Solutions Japan, and Pfizer Inc., built a hybrid model combining a decision tree for the initial induction phase with a Markov framework for maintenance and all subsequent lines of therapy. Patients who failed their first advanced therapy were assumed to switch to an alternative agent, then to a basket of remaining drugs, and eventually to best supportive care if they continued to lose response. The simulated population mirrored Japanese trial participants newly starting advanced therapy, with a mean age of 42.4 years and a mean body weight of 59.7 kilograms. Efficacy and safety inputs came from a Bayesian network meta-analysis covering ten advanced therapies, supplemented with Japan-specific costs drawn from a nationwide claims database and adjusted to 2025 price levels.

The economics were evaluated from the perspective of the Japanese payer, with both costs and quality-adjusted life years discounted at an annual rate of 2.0 percent, in line with national health technology assessment guidelines. The willingness-to-pay threshold was set at JPY 7,500,000 per QALY, roughly USD 49,547, the benchmark used in Japan’s system for designated intractable diseases, a category to which ulcerative colitis belongs. Only serious infections were modelled as adverse events, a choice consistent with previous economic evaluations in this therapeutic area, because they drive the greatest costs and quality-of-life impairment while safety profiles across the drug classes remain broadly similar.

The central result was striking in its clarity. Among all 79 sequences evaluated, starting with etrasimod and following with upadacitinib produced the greatest lifetime health benefit, a total of 17.801 quality-adjusted life years. Four strategies anchored the efficiency frontier, the curve tracing the most efficient options at each cost level: infliximab followed by ustekinumab, infliximab followed by etrasimod, infliximab followed by upadacitinib, and etrasimod followed by upadacitinib. Each successive step along the frontier bought more health at an incremental cost-effectiveness ratio comfortably below the Japanese threshold, culminating in etrasimod followed by upadacitinib at JPY 6,684,442 per QALY, which remained cost-effective and delivered the most value overall.

The mechanistic logic behind the winning sequence is instructive. The network meta-analysis showed that upadacitinib, an oral JAK inhibitor, achieved the highest remission and response rates among patients who had already been exposed to advanced therapy, making it a particularly powerful second-line option. Etrasimod, which traps lymphocytes in lymph nodes by modulating the S1P receptor on their surface and thereby blunts intestinal inflammation while preserving systemic immune surveillance, showed favorable efficacy and safety across multiple endpoints in treatment-naïve patients. Pairing the two oral agents in that order therefore maximized cumulative quality-adjusted survival, and etrasimod outperformed ozanimod, its identically priced oral counterpart, on maintenance response, remission, and serious infection rates in the comparative evidence underpinning the model.

Sensitivity analyses revealed where the conclusion could shift. When infliximab and adalimumab biosimilars were introduced into the model, the picture changed materially. Because biosimilar infliximab costs JPY 13,860 per 100-milligram vial compared with JPY 35,981 for the originator, a first-line biosimilar infliximab sequence followed by upadacitinib became the most cost-effective strategy, pushing the etrasimod-upadacitinib combination above the threshold. Yet the authors caution that real-world biosimilar uptake in Japanese ulcerative colitis remains around 20 percent, and a survey found that 85 percent of Japanese inflammatory bowel disease patients were unaware biosimilars even existed. Under Japan’s high-cost medical expense benefit program, out-of-pocket costs are so constrained that patients have little financial incentive to switch.

Other scenario analyses tested alternative assumptions about disease progression and treatment intensity. Allowing dose escalation of tofacitinib, upadacitinib, and ustekinumab during maintenance left etrasimod followed by upadacitinib as the most cost-effective sequence, though with a narrower margin. Assuming patients never transitioned from later-line therapy to best supportive care shifted the optimal sequence to etrasimod followed by ustekinumab. Applying higher colectomy rates, informed by Japanese national database studies, moved infliximab followed by upadacitinib to the top. The fragility of the base-case result was further underlined by the one-way sensitivity analysis, in which placebo-arm maintenance parameters and infliximab’s relative efficacy had the largest influence on the incremental net monetary benefit.

The study carries important caveats that temper any temptation to treat its ranking as clinical gospel. Efficacy estimates derive from a network meta-analysis of trials published through November 2022, and such analyses for ulcerative colitis are known to suffer from heterogeneity in prior biologic exposure, baseline disease activity, and outcome definitions. Real-world evidence, which now exists for several of the agents, was excluded because of incomparability across studies. Serious infections were the only adverse event modelled, leaving unquantified risks such as major cardiovascular events, venous thromboembolism, herpes zoster, and malignancy, factors that matter greatly in real treatment choices. Utility values came largely from non-Japanese populations, and the transition rate from late-line therapy to best supportive care was borrowed from a United States claims database.

There is also the question of who conducted the analysis. All clinical authors are Pfizer employees or contractors funded by Pfizer Japan, and the company financed the research and publication. The acknowledged conflicts do not invalidate the mathematics, but they do mean the framing of etrasimod, a Pfizer drug, as the preferred starting point deserves independent scrutiny, particularly given how sensitive the results were to pricing assumptions around cheaper biosimilars.

For clinicians and policymakers, the study’s value lies less in crowning a single winner than in demonstrating that sequencing choices carry quantifiable economic and health consequences over a lifetime of disease. The authors themselves stress that the findings should complement, not dictate, clinical judgement, alongside patient age, comorbidities, pregnancy plans, and personal preference. As Japan’s ulcerative colitis population grows, having expanded roughly 1.4-fold over eight years, and as real-world data accumulate on the newer oral agents, future updates of this model will be needed to confirm whether the etrasimod-then-upadacitinib pathway truly delivers the best value in everyday practice rather than in simulation.

Subject of Research: Cost-effectiveness modeling of advanced therapy sequences for moderately to severely active ulcerative colitis in Japan

Article Title: Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan

Article References: Kamei, K., Enami, M., Matsuda, H., Yamagami, K., Dai, Y., Hoshi, M., Law, E. H., & Yuasa, A. (2026). Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan. Advances in Therapy. https://doi.org/10.1007/s12325-026-03757-3

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03757-3

Keywords: ulcerative colitis, cost-effectiveness, etrasimod, upadacitinib, infliximab, S1P receptor modulators, JAK inhibitors, network meta-analysis, QALY, Japan, biosimilars, treatment sequencing

The research team, led by analysts at the York Health Economics Consortium and clinicians at Manchester University NHS Foundation Trust, built a cost-effectiveness model aligned with the National Institute for Health and Care Excellence reference case. They simulated four distinct patient populations: people with early-stage lung cancer (stages 1 to 3a), people with late-stage head and neck cancer (stages 3 and 4), people with kidney cancer at any stage, and an exploratory general cancer population mixing several diagnoses. In every population examined, offering cessation support at diagnosis proved cost effective against the standard threshold of £20,000 per quality-adjusted life year, or QALY, gained.

The technical machinery behind the analysis is considerable. The model tracked a cohort of adults aged 18 and over who had recently been diagnosed with cancer and currently smoked, splitting them into those who quit and those who continued based on natural quit rates, service uptake, and five-year relapse rates. Each group then moved through a partitioned survival model with three health states: progression-free disease, progressed disease, and death. Survival trajectories were derived from published Kaplan–Meier curves, which the team digitised and converted into pseudo-individual participant data using the Guyot algorithm, before fitting six standard parametric distributions — exponential, Weibull, Gompertz, log-normal, log-logistic, and generalised gamma — to extrapolate long-term overall and progression-free survival beyond the observed follow-up periods.

Beyond cancer itself, the model accounted for seven smoking-related comorbidities: chronic obstructive pulmonary disease, coronary heart disease, myocardial infarction, type 2 diabetes, stroke, dementia, and asthma. Age- and gender-specific prevalence estimates for non-smokers were multiplied by smoking-status relative risks to generate weighted comorbidity risks for quitters and continuing smokers alike. Costs and QALYs were discounted at 3.5 percent per annum over a lifetime horizon — 25 years for the lung cancer cohort and 30 years for the others — with monthly cycles capturing clinical events, treatment costs, and health-related quality of life.

The headline numbers are striking in their asymmetry. In the lung cancer population, median time to death rose from 4.08 to 4.25 years, at an incremental cost of just £292 per person, yielding an incremental cost-effectiveness ratio of £2,606 per QALY. For head and neck cancer, median survival improved by four months at an additional £1,074 per person, an ICER of £5,495. Kidney cancer delivered the most emphatic result: the intervention was dominant, meaning it both saved money — £189 per person — and added 0.45 QALYs, driven by reduced spending on second-line treatment and end-of-life care. The general cancer population gained 0.10 QALYs at £392 extra per person, an ICER of £4,055.

Probabilistic sensitivity analysis, run across 1,000 iterations, reinforced confidence in these findings. Smoking cessation at diagnosis remained cost effective in 99.70 percent of iterations for lung cancer, 99.90 percent for head and neck cancer, 100 percent for kidney cancer, and 97.80 percent for the general cancer population. In the kidney cancer scenario, the intervention was outright dominant — cheaper and better — in 70.40 percent of simulations. Threshold analyses identified the boundaries of the result: the intervention stops being cost effective only if uptake falls below roughly 12 to 14 percent, or if the per-person implementation cost climbs above £2,000 to £6,600 depending on the population. Both boundaries sit comfortably away from realistic estimates, since uptake of cessation support offered during lung cancer screening in the UK has been measured at around 74 percent.

The biological rationale for the survival gains is well established. Smoking during treatment impairs overall survival, raises cancer-specific mortality, and increases treatment-related complications such as surgical site infections and pulmonary problems after surgery. Tobacco alters the biological characteristics of cancer cells and speeds the metabolism of anticancer drugs, meaning chemotherapeutic agents are cleared faster in smokers. Conversely, quitting after diagnosis has been shown in prospective cohort studies to reduce the risk of progression, cancer-specific death, and all-cause mortality compared with continued smoking. The model’s assumption that treatments themselves do not differ by smoking status is therefore conservative, since patients who quit may in fact be eligible for more treatment options, including surgery.

Scaled across the population, the implications are substantial. Around 57,000 cases of cancer are attributed to smoking in the UK each year, and the authors estimate that rolling out cessation services at diagnosis could generate a net monetary benefit upwards of £88 million based on the general cancer population. The cost of the cessation package itself — an estimated £257 per person, including an e-consultation proxy cost of £45.98 to cover NHS system restructuring and the pharmacological and behavioural treatments — represents between 0.34 and 0.53 percent of the total costs the NHS incurs during cancer care. By comparison, NICE-recommended immunotherapies such as durvalumab for limited-stage small cell lung cancer cost an estimated £141,335 per person, and nivolumab for head and neck cancer around £31,693.

The study is not without limitations, and the authors are candid about them. Survival data for the lung and kidney cancer populations came from a Russian cohort, an assumption judged reasonable by consulting oncologists who found no genetic or population characteristics that would materially alter outcomes in a UK setting. The Kaplan–Meier studies were predominantly male — roughly 80 percent across the three cancer-specific populations, against 50 to 70 percent in the wider cancer population — and natural quit rates and relapse rates were drawn from non-cancer populations due to data scarcity. The general cancer analysis required averaging costs and utilities across tumour types, and the authors caution that its results should be treated as exploratory. Several assumptions, such as equal relapse rates in each year after the first and identical treatment regardless of smoking status, deliberately bias the model against the intervention.

Beyond the immediate clinical economics, the findings carry broader significance. Tobacco smoking remains the largest single cause of health inequalities in England, and cancer mortality is almost 60 percent higher in the most deprived areas compared with the least; prior distributional cost-effectiveness work suggests cessation interventions reduce absolute health inequality. Reducing smoking would also cut second-hand smoke exposure, which is linked to ischaemic heart disease, COPD, respiratory infections, and stroke. The authors note that embedding cessation at diagnosis aligns squarely with the NHS 10-year plan’s stated shift from treating sickness to preventing it, and that effective first-line cancer treatment in non-smokers should reduce demand for costly second-line care. The remaining challenge, they conclude, is practical: delivering integrated services will require initial investment in staff and capacity, and policymakers must weigh rollout against the demonstrated value for money that this analysis makes abundantly clear.

Subject of Research: Cost-effectiveness of integrating smoking cessation services into NHS cancer care pathways in England

Article Title: Economic and health impact of integrating smoking cessation services into NHS cancer care pathways in England: a modelling study

Article References: Green, M., Harper, S., Telfer-Thomas, E., Agrawal, S., Callister, M. E., Lane, J. L., Warren, G., Murray, R. L., Evison, M., Sheikh, M., & Malcolm, R. (2026). Economic and health impact of integrating smoking cessation services into NHS cancer care pathways in England: a modelling study. The Lancet Regional Health – Europe, 71, Article 101869. https://doi.org/10.1016/j.lanepe.2026.101869

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101869

Keywords: smoking cessation, cancer care, cost-effectiveness, NHS, health economics, QALY, lung cancer, head and neck cancer, kidney cancer, tobacco, modelling study, health inequalities

The research team, led by Addisu Shunu Beyene of the University of Newcastle and including colleagues from Deakin University, Haramaya University, the University of Southern Queensland, and the University of Melbourne, drew on the Household, Income and Labour Dynamics in Australia Survey, one of the world’s most respected nationally representative panel studies. Rather than relying on a single snapshot in time, the investigators exploited waves 9, 13, 17, and 21 of the survey, capturing data spanning roughly thirteen years of Australian life. The analytical sample comprised 27,564 person-year observations drawn from 11,042 individuals, a scale and temporal depth that allow researchers to distinguish genuine disease effects from the noise of cross-sectional comparisons.

Methodologically, the study stands out for its use of fixed-effects regression models, a technique prized in health and social science research because it controls for all time-invariant characteristics of individuals, whether observed or not. In practical terms, each person in the sample effectively serves as their own control: the analysis asks whether quality of life changes when the same person develops diabetes, net of stable traits such as genetics, early-life circumstances, personality, and enduring socioeconomic background. This design substantially reduces the risk of confounding, one of the most persistent problems in observational studies of chronic disease, although it cannot entirely eliminate biases arising from time-varying unmeasured factors.

The outcome measures were equally rigorous. Health-related quality of life was assessed with the Short Form 36 questionnaire, a widely validated instrument whose physical and mental subscales are summarized in the Physical Component Summary and Mental Component Summary scores. From these responses, the researchers derived the SF-6D health-state utility value, a preference-based index scored between zero and one that represents how much a given health state is valued relative to full health and death. Utility values of this kind are the currency of quality-adjusted life years, or QALYs, the metric underpinning cost-effectiveness evaluations by agencies such as Australia’s Pharmaceutical Benefits Advisory Committee and health technology assessment bodies worldwide.

The central result was unambiguous. Type 2 diabetes was significantly associated with lower Physical Component Summary scores, with a coefficient of −1.01 points and a 95 percent confidence interval running from −1.62 to −0.41. The disease also reduced SF-6D utility values by −0.0080 points, with a confidence interval from −0.0154 to −0.0007. While these utility decrements may appear numerically small, health economists caution that even modest per-person decrements accumulate across millions of affected individuals and across years of remaining life, translating into large population-level losses of quality-adjusted survival. In contrast, the study found no statistically significant association between type 2 diabetes and the Mental Component Summary, indicating that the burden of the disease in this population is concentrated primarily in physical functioning rather than psychological wellbeing.

The subgroup analyses added a crucial layer of nuance. The negative effects on physical quality of life and utility were most pronounced among men and among adults aged 60 years and older, groups that already face elevated vulnerability to the vascular and musculoskeletal consequences of prolonged hyperglycemia. Additional analyses revealed a heavier physical quality-of-life burden among participants with insufficient physical activity, those living with disability, smokers, people who consumed alcohol, and certain income groups. These patterns suggest that diabetes does not act in isolation but compounds existing disadvantages, deepening inequalities in how long and how well people live with the disease.

The biological plausibility behind these findings is well established. Chronic hyperglycemia accelerates atherosclerosis, impairs microvascular circulation, promotes peripheral neuropathy, and contributes to muscle wasting, fatigue, and reduced mobility, all of which directly degrade the physical dimensions of quality of life captured by the SF-36. Diabetes also increases susceptibility to infections, delays wound healing, and raises the likelihood of amputations and vision loss, each of which imposes profound limitations on daily activities. The absence of a significant mental health effect in this study contrasts with some earlier cross-sectional research and may reflect the adaptive capacities of long-term survey respondents, the protective effects of Australia’s healthcare access, or the fixed-effects design filtering out persistent psychological vulnerabilities that correlate with diabetes onset.

What elevates this study’s importance beyond epidemiology is its explicit focus on health economic implications. The authors emphasize that the estimated SF-6D utility decrements provide exactly the kind of evidence needed to populate QALY-based economic evaluations of diabetes prevention and management interventions. Historically, utility inputs for such models have often been borrowed from other countries, other instruments, or cross-sectional data of uncertain quality, introducing uncertainty into cost-effectiveness estimates. By generating nationally representative, longitudinal, within-person estimates from Australian data, the study offers modelers a more defensible foundation for judging whether prevention programs, screening initiatives, new therapies, or lifestyle interventions deliver value for money.

The findings also carry direct implications for clinical practice. The authors argue that health-related quality of life assessment deserves a place in routine diabetes care, not merely as an afterthought but as a core outcome that reflects what matters most to patients. Because the heaviest burdens fell on older men, people with sedentary lifestyles, smokers, and those drinking alcohol, the results support targeted prevention and management strategies that promote regular physical activity, smoking cessation, and moderation of alcohol consumption. In an era when diabetes prevalence continues to climb globally, the message from this thirteen-year Australian journey is clear: the disease steals not only years of life but the quality of the years that remain, and measuring that theft is the first step toward preventing it.

Subject of Research: Impact of type 2 diabetes mellitus on health-related quality of life and health-state utility values in middle-aged and older Australians

Article Title: Decrements in Health-Related Quality of Life and Health-State Utility Value Due to Type 2 Diabetes Mellitus: Implications for Future Health Economic Evaluation

Article References: Beyene, A. S., Ushula, T. W., Roba, H. S., Alam, K., & Keramat, S. A. (2026). Decrements in Health-Related Quality of Life and Health-State Utility Value Due to Type 2 Diabetes Mellitus: Implications for Future Health Economic Evaluation. Applied Research in Quality of Life. https://doi.org/10.1007/s11482-026-10672-w

Image Credits: AI Generated

DOI: 10.1007/s11482-026-10672-w

Keywords: type 2 diabetes, health-related quality of life, SF-6D utility value, HILDA Survey, fixed-effects regression, QALY, health economics, Australia, Physical Component Summary, longitudinal study, health economic evaluation, diabetes complications